US4675382A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hybrid protein
Assignee: Harvard University
•
Filing: 1985-11-06
•
Granted: 1987-06-23
•
Expires: 2005-11-06
Abstract
Abstract A hybrid protein including protein fragments joined together by peptide bonds, the hybrid protein including, in sequential order, beginning at the amino terminal end of the hybrid protein, (a) the enzymatically active Fragment A of diphtheria (b) a fragment including the cleavage domain 1 1 adjacent the Fragment A of diphtheria toxin, (c) a fragment including at least a portion of the hydrophobic domain of Fragment B of diphtheria toxin and not including the generalized eukaryotic binding site of the Fragment B, and (d) a fragment including a portion of a cell-specific polypeptide ligand, the portion including at least a portion of the binding domain of the polypeptide ligand, the portion of the binding domain being effective to cause the hybrid protein to bind selectively to a predetermined class of cells to be attacked by the enzymatically active Fragment A.
Inventors
- 👤 John R. Murphy
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 17:41
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/195; C07K14/34; C07K14/435; C07K14/575; C07K14/665; C07K14/68; C07K14/685; C07K14/69; A; A61; A61K; A61K38/00; C07K2319/00; C07K2319/55; C07K2319/70; C07K2319/74; C07K2319/75; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/31
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
141 words
A hybrid protein comprising protein fragments joined together by peptide bonds, said hybrid protein comprising, in sequential order, beginning at the amino terminal end of said hybrid protein, (a) the enzymatically active Fragment A of diphtheria toxin, (b) a fragment including the cleavage domain 1 1 adjacent said Fragment A of diphtheria toxin, (c) a fragment comprising at least a portion of the hydrophobic domain of Fragment B of diphtheria toxin and not including the generalized eukaryotic binding site of said Fragment B, and (d) a fragment comprising a portion of a cell-specific polypeptide ligand, said portion including at least a portion of the binding domain of said polypeptide ligand, said portion of said binding domain being effective to cause said hybrid protein to bind selectively to a predetermined class of cells to be attacked by said enzymatically active Fragment A.
Claim 2
Dependent Claim
141 words
A hybrid protein comprising protein fragments joined together by peptide bonds, said hybrid protein comprising, in sequential order, beginning at the amino terminal end of said hybrid protein, (a) the enzymatically active Fragment A of diphtheria toxin, (b) a fragment including the cleavage domain 1 1 adjacent said Fragment A of diphtheria toxin, (c) a fragment comprising at least a portion of the hydrophobic domain of Fragment B of diphtheria toxin and not including the generalized eukaryotic binding site of said Fragment B, and (d) a fragment comprising a portion of a cell-specific polypeptide ligand, said portion including at least a portion of the binding domain of said polypeptide ligand, said portion of said binding domain being effective to cause said hybrid protein to bind selectively to a predetermined class of cells to be attacked by said enzymatically active Fragment A.
Claim 3
Dependent Claim
34 words
The hybrid protein of claim 1 wherein said fragment (c) is encoded by the portion of the diphtheria toxin Fragment B encoding gene fragment between 1 1 and the position of the NruI site.
Claim 4
Dependent Claim
16 words
The hybrid protein of claim 2, further comprising fragment 1 2 between fragments (c) and (d).
Claim 5
Dependent Claim
24 words
The hybrid protein of claim 1 wherein said hybrid protein is coded for by a fused gene comprising regions coding for said protein fragments.
Claim 6
Dependent Claim
13 words
The hybrid protein of claim 1 wherein said polypeptide ligand is a hormone.
Claim 7
Dependent Claim
35 words
The hybrid protein of claim 5 wherein said portion of said polypeptide hormone is a portion of α or β melanocyte stimulating hormone effective to cause said hybrid protein to bind to malignant melanocyte cells.
Claim 8
Dependent Claim
31 words
The hybrid protein of claim 5 wherein said portion of said polypeptide hormone is a portion of substance P effective to cause said hybrid protein to bind to pain receptor neurons.
Claim 9
Dependent Claim
30 words
The hybrid protein of claim 5 wherein said portion of said polypeptide hormone is a portion of interleukin I effective to cause said hybrid protein to bind to T cells.
Claim 10
Dependent Claim
30 words
The hybrid protein of claim 5 wherein said portion of said polypeptide hormone is a portion of interleukin II effective to cause said hybrid protein to bind to T cells.
Claim 11
Dependent Claim
30 words
The hybrid protein of claim 5 wherein said portion of said polypeptide hormone is a portion of interleukin III effective to cause said hybrid protein to bind to T cells.
References Cited (Backward Citations)
US4201770A
Cited
US4082613A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-06-22 | 1990-12-22 | 1991-06-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-06-22 | 1994-12-22 | 1995-06-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-06-22 | 1998-12-22 | 1999-06-23 | $7700.00 | Window Closed / Lapsed |